Trial Profile
An open-label, multicenter, single-arm, Phase I dose-escalation with efficacy tail extension study of vemurafenib (RO5185426) in pediatric patients with surgically incurable and unresectable Stage IIIC or Stage IV melanoma harboring BRAFV600 mutations
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms BRIM-P
- Sponsors Roche
- 31 Jul 2021 This trial has been completed in Spain according to European Clinical Trials Database record.
- 27 Jul 2020 This trial has been completed in United Kingdom according to European Clinical Trials Database record.
- 17 Jun 2016 Status changed from recruiting to discontinued due to low enrollment.